TIME OF PERMANENCE IN SECOND OR SUCCESSIVE LINES OF TREATMENT WITH ANTI-TNF DRUGS VS OTHER BIOLOGICAL DRUGS IN PATIENTS WITH INFLAMMATORY ARTHROPATHIES